Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The Food and Drug Administration cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor indicated for children ages 2 and older who do not use insulin. The decision builds on an earlier clearance that authorized the same device for adults 18 and older, and it removes one of the most significant access barriers for families trying to track glucose trends in kids outside of clinical settings.
Why removing the prescription barrier changes the calculus for families
Continuous glucose monitors have been available by prescription for years, but the requirement meant a parent had to secure a clinician’s order, often after navigating insurance pre-authorization, before placing a sensor on a child’s arm. The new clearance sidesteps that process entirely for a specific group: children who are not on insulin and who face no significant risk of dangerously low blood sugar. According to the FDA’s device classification, the over-the-counter integrated continuous glucose monitor category carries Class II status and is intended for people not on insulin, explicitly excluding devices designed to control insulin delivery.
That distinction matters because it defines who the device is for and, just as critically, who it is not for. A child with Type 1 diabetes on an insulin pump falls outside this indication. The target user is a child whose pediatrician or parent has flagged rising glucose levels, perhaps linked to weight gain or prediabetic markers, and who could benefit from real-time trend data without the overhead of a prescription pathway. The hypothesis that parents will try Stelo faster than prescription alternatives rests on a straightforward logic: when the friction of obtaining a medical device drops to a retail purchase, short-term experimentation becomes far easier. Whether that trial use translates into sustained adoption or meaningful health outcomes is a separate, unanswered question.
Removing the prescription requirement also changes how families might interact with the health system. Instead of waiting for a formal diagnosis, some parents could buy a sensor at a pharmacy or online and begin tracking patterns on their own. That autonomy may empower families who feel their concerns have been dismissed, but it could also lead to data being collected without the context a clinician provides. Parents may see normal post-meal spikes as alarming or misinterpret day-to-day variability as evidence of a serious problem. In that sense, easier access magnifies both the potential benefits and the risks of misunderstanding.
Dexcom’s Stelo clearance and the regulatory record behind it
The FDA’s adult decision, which made Stelo the first OTC continuous glucose monitor for people 18 and older not using insulin, is documented in an agency press communication that framed the device as a tool for individuals with diabetes who are not on insulin, as well as for people who simply want to understand how diet and exercise affect their glucose. The pediatric authorization is described in a separate FDA announcement for children, which extends the indication to ages 2 and up under the same non-insulin-user restriction. Dexcom is listed as the applicant on the 510(k) premarket notification, submission number K234070.
The device works by placing a small sensor on the skin that measures glucose in interstitial fluid and transmits readings to a smartphone app. It does not replace fingerstick blood glucose meters for making treatment decisions in insulin-dependent patients, and the FDA’s classification explicitly states the OTC category excludes monitors intended to control insulin delivery. The regulatory framework treats this as a monitoring tool for trend awareness rather than a device for dosing decisions, which is why it qualifies for over-the-counter sale instead of being tied to a prescription and tighter clinical oversight.
One tension in the record deserves attention. The adult clearance described Stelo as authorized for those 18 and older who do not use insulin, while the newer announcement extends the same device to ages 2 and up. Both clearances share identical safety boundaries, meaning the accuracy and performance standards applied to the adult version are the same ones governing use in a 3-year-old. No publicly linked clinical performance data specific to pediatric subjects from the K234070 submission has appeared in the FDA’s clearance notices. That gap leaves open the question of whether sensor accuracy in small children, whose body composition and activity levels differ from adults, was evaluated through dedicated pediatric trials or extrapolated from adult data.
The FDA has also drawn a sharp line between cleared glucose monitors and consumer wearables. In its public messaging, the agency has warned consumers not to rely on smartwatches or smart rings that claim to measure blood glucose without using needles or drawing blood, citing the risk of inaccurate readings from products that have not undergone regulatory review. Those warnings reinforce the distinction between Stelo, which passed the 510(k) process, and unregulated devices that market similar capabilities without evidence. For parents, that difference may be easy to miss in a crowded marketplace, but from a regulatory standpoint it is central: one category has been evaluated for accuracy and safety within defined limits, the other has not.
Open questions about pediatric glucose monitoring without a prescription
Several practical unknowns surround this clearance. First, no direct statements from Dexcom or pediatric endocrinologists about real-world use in children ages 2 through 17 appear in the primary FDA sources. Clinicians who treat pediatric metabolic conditions have not weighed in publicly, at least not through the channels documented in the clearance record, on whether unsupervised parental use of a CGM could lead to unnecessary anxiety, dietary restriction, or misinterpretation of normal glucose fluctuations in growing children.
Second, the FDA’s clearance notices do not detail any post-market surveillance plans specific to the pediatric OTC indication. For a device newly available without a prescription to children as young as 2, the absence of a publicly described monitoring framework raises questions about how the agency and Dexcom plan to track adverse events, sensor adhesion failures, or patterns of off-label use. Standard medical device reporting rules still apply, but it is not clear from the public record whether parents and primary care clinicians will receive targeted guidance on when and how to report problems.
Third, there is the issue of health equity. Over-the-counter status removes the prescription barrier, but it does not address cost. The FDA documents do not discuss pricing, insurance coverage, or whether Stelo will be eligible for reimbursement when purchased without a prescription. Families with higher incomes may be able to experiment freely with sensors, while lower-income parents could remain dependent on traditional pathways that require both a prescription and insurer approval. In that sense, OTC access may widen options for some households without fully closing gaps for others.
Finally, the broader impact on pediatric care pathways remains uncertain. Primary care pediatricians may begin seeing more families who arrive with weeks of glucose data collected outside clinical supervision. That information could help identify early metabolic problems, but it might also generate false alarms and additional testing. Specialists, in turn, may need to clarify when OTC CGM use is appropriate and when a child’s profile warrants a transition to prescription-grade devices and closer follow-up. Until more real-world experience accumulates and is publicly reported, those practice patterns will likely evolve case by case.
For now, the Stelo pediatric clearance marks a notable shift: continuous glucose monitoring, once tightly tethered to prescriptions and insulin therapy, is moving into the retail sphere for very young children who do not use insulin. The FDA’s decisions outline the boundaries of that experiment, but they leave many practical and clinical questions to be answered in the years ahead by families, clinicians, and regulators watching how the technology is used outside the clinic.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
